Logo image of EVOK

EVOKE PHARMA INC (EVOK) Stock Fundamental Analysis

NASDAQ:EVOK - Nasdaq - US30049G3020 - Common Stock - Currency: USD

4.61  -0.27 (-5.53%)

After market: 4.63 +0.02 (+0.43%)

Fundamental Rating

3

EVOK gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. EVOK has a bad profitability rating. Also its financial health evaluation is rather negative. EVOK is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

EVOK had negative earnings in the past year.
In the past year EVOK has reported a negative cash flow from operations.
In the past 5 years EVOK always reported negative net income.
In the past 5 years EVOK always reported negative operating cash flow.
EVOK Yearly Net Income VS EBIT VS OCF VS FCFEVOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

EVOK's Return On Assets of -31.01% is in line compared to the rest of the industry. EVOK outperforms 51.30% of its industry peers.
Looking at the Return On Equity, with a value of -86.94%, EVOK is in line with its industry, outperforming 43.01% of the companies in the same industry.
Industry RankSector Rank
ROA -31.01%
ROE -86.94%
ROIC N/A
ROA(3y)-70.05%
ROA(5y)-86.08%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVOK Yearly ROA, ROE, ROICEVOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

The Gross Margin of EVOK (97.36%) is better than 97.93% of its industry peers.
In the last couple of years the Gross Margin of EVOK has grown nicely.
EVOK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.62%
GM growth 5YN/A
EVOK Yearly Profit, Operating, Gross MarginsEVOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for EVOK has been increased compared to 1 year ago.
Compared to 5 years ago, EVOK has less shares outstanding
The debt/assets ratio for EVOK has been reduced compared to a year ago.
EVOK Yearly Shares OutstandingEVOK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
EVOK Yearly Total Debt VS Total AssetsEVOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

EVOK has an Altman-Z score of -10.59. This is a bad value and indicates that EVOK is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of EVOK (-10.59) is worse than 70.98% of its industry peers.
A Debt/Equity ratio of 0.86 indicates that EVOK is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.86, EVOK is not doing good in the industry: 70.47% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Altman-Z -10.59
ROIC/WACCN/A
WACCN/A
EVOK Yearly LT Debt VS Equity VS FCFEVOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 1.55 indicates that EVOK should not have too much problems paying its short term obligations.
With a Current ratio value of 1.55, EVOK is not doing good in the industry: 69.43% of the companies in the same industry are doing better.
A Quick Ratio of 1.50 indicates that EVOK should not have too much problems paying its short term obligations.
EVOK's Quick ratio of 1.50 is on the low side compared to the rest of the industry. EVOK is outperformed by 63.21% of its industry peers.
Industry RankSector Rank
Current Ratio 1.55
Quick Ratio 1.5
EVOK Yearly Current Assets VS Current LiabilitesEVOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 86.29% over the past year.
The Revenue has grown by 90.02% in the past year. This is a very strong growth!
The Revenue has been growing by 84.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)86.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)90.02%
Revenue growth 3Y84.95%
Revenue growth 5YN/A
Sales Q2Q%77.47%

3.2 Future

EVOK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.19% yearly.
Based on estimates for the next years, EVOK will show a very strong growth in Revenue. The Revenue will grow by 52.59% on average per year.
EPS Next Y77.31%
EPS Next 2Y52.8%
EPS Next 3Y37.19%
EPS Next 5YN/A
Revenue Next Year58.22%
Revenue Next 2Y58.67%
Revenue Next 3Y52.59%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
EVOK Yearly Revenue VS EstimatesEVOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
EVOK Yearly EPS VS EstimatesEVOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -100 -200 -300

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EVOK. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 3.03, which indicates a rather cheap valuation of EVOK.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EVOK indicates a rather cheap valuation: EVOK is cheaper than 97.41% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of EVOK to the average of the S&P500 Index (36.52), we can say EVOK is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 3.03
EVOK Price Earnings VS Forward Price EarningsEVOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVOK Per share dataEVOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

EVOK's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as EVOK's earnings are expected to grow with 37.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.8%
EPS Next 3Y37.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EVOK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOKE PHARMA INC

NASDAQ:EVOK (7/17/2025, 8:20:27 PM)

After market: 4.63 +0.02 (+0.43%)

4.61

-0.27 (-5.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-07 2025-08-07
Inst Owners16.93%
Inst Owner Change0%
Ins Owners1.18%
Ins Owner Change0.59%
Market Cap6.87M
Analysts82.86
Price Target18.36 (298.26%)
Short Float %0.81%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-24.78%
Min EPS beat(2)-51.52%
Max EPS beat(2)1.96%
EPS beat(4)1
Avg EPS beat(4)-54.68%
Min EPS beat(4)-142.52%
Max EPS beat(4)1.96%
EPS beat(8)4
Avg EPS beat(8)-21.2%
EPS beat(12)6
Avg EPS beat(12)-15.5%
EPS beat(16)9
Avg EPS beat(16)-12.56%
Revenue beat(2)1
Avg Revenue beat(2)-1.87%
Min Revenue beat(2)-8.93%
Max Revenue beat(2)5.18%
Revenue beat(4)1
Avg Revenue beat(4)-10.59%
Min Revenue beat(4)-22.51%
Max Revenue beat(4)5.18%
Revenue beat(8)4
Avg Revenue beat(8)-4.95%
Revenue beat(12)5
Avg Revenue beat(12)-4.35%
Revenue beat(16)7
Avg Revenue beat(16)5.56%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-30.43%
EPS NY rev (1m)0%
EPS NY rev (3m)-24.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.03
P/S 0.59
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB 1.18
EV/EBITDA N/A
EPS(TTM)-3.01
EYN/A
EPS(NY)1.52
Fwd EY32.97%
FCF(TTM)-2.6
FCFYN/A
OCF(TTM)-2.6
OCFYN/A
SpS7.78
BVpS3.92
TBVpS3.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.01%
ROE -86.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.36%
FCFM N/A
ROA(3y)-70.05%
ROA(5y)-86.08%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.62%
GM growth 5YN/A
F-Score5
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.55
Quick Ratio 1.5
Altman-Z -10.59
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y77.31%
EPS Next 2Y52.8%
EPS Next 3Y37.19%
EPS Next 5YN/A
Revenue 1Y (TTM)90.02%
Revenue growth 3Y84.95%
Revenue growth 5YN/A
Sales Q2Q%77.47%
Revenue Next Year58.22%
Revenue Next 2Y58.67%
Revenue Next 3Y52.59%
Revenue Next 5YN/A
EBIT growth 1Y26.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y41.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.35%
OCF growth 3YN/A
OCF growth 5YN/A